Literature DB >> 19448569

Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn's disease.

Carlos Taxonera1, Luis Rodrigo, Francesc Casellas, Xavier Calvet, Federico Gómez-Camacho, Daniel Ginard, Manuel Castro, Luisa Castro, Marta Ponce, Pilar Martínez-Montiel, Elena Ricart, Javier P Gisbert, Antonio López-San Román, José M Morales, Miguel A Casado.   

Abstract

GOALS: To estimate the impact of infliximab (IFX) maintenance therapy on the use of hospital resources in patients with Crohn's disease (CD). STUDY: Medical records of patients treated with IFX maintenance therapy (5 mg/kg body weight; intravenous infusion) for luminal (L) or fistulizing (F) CD at 13 hospitals were retrospectively reviewed. Patients were assessed as their own controls. Use of CD-related healthcare resources was recorded comparing 1-year periods before and after first IFX infusion (pre-IFX and post-IFX).
RESULTS: One hundred fifty-three CD patients (n=84 L; 69 F) fulfilled the inclusion criteria. Mean number of IFX infusions was 7/y with an average of 335 mg/infusion dose/patient. During the pre-IFX period, 55% of patients needed hospitalization versus 31% in the post-IFX period (P<0.001). Mean inpatient stay was 11.3 d/y [11.2 (L), 11.5 (F)] for the pre-IFX period, and 6.3 d/y [6.2 (L), 6.3 (F)] in the post-IFX period (P<0.001). Surgery was required in 24% patients in the pre-IFX period and in 11% post-IFX (P<0.001). There were no significant changes in the incidence of outpatient visits although emergency room visits fell significantly.
CONCLUSIONS: Maintenance IFX in CD patients is associated with decreases in the use and length of hospitalizations and the need for surgery in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19448569     DOI: 10.1097/MCG.0b013e3181986917

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  6 in total

1.  Utilization trends of anti-TNF agents and health outcomes in adults and children with inflammatory bowel diseases: a single-center experience.

Authors:  K T Park; Aaron Sin; May Wu; Dorsey Bass; Jay Bhattacharya
Journal:  Inflamm Bowel Dis       Date:  2014-07       Impact factor: 5.325

2.  Resource use and cost of care with biologicals in Crohn's disease in South Africa: a retrospective analysis from a payer perspective.

Authors:  Jacqui Miot; Susan Smith; Niri Bhimsan
Journal:  Int J Clin Pharm       Date:  2016-04-27

3.  Health care resource use and costs in Crohn's disease before and after infliximab therapy.

Authors:  Dustin E Loomes; Christopher Teshima; Philip Jacobs; Richard N Fedorak
Journal:  Can J Gastroenterol       Date:  2011-09       Impact factor: 3.522

Review 4.  How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease.

Authors:  Parambir S Dulai; Siddharth Singh; Niels V Casteele; Brigid S Boland; William J Sandborn
Journal:  Inflamm Bowel Dis       Date:  2016-04       Impact factor: 5.325

5.  Thirty-day mortality after elective and emergency total colectomy in Danish patients with inflammatory bowel disease: a population-based nationwide cohort study.

Authors:  Anders Tøttrup; Rune Erichsen; Claus Sværke; Søren Laurberg; Henrik Toft Srensen
Journal:  BMJ Open       Date:  2012-04-05       Impact factor: 2.692

6.  A systemic review and metaanalysis of postoperative outcomes in urgent and elective bowel resection in patients with Crohn's disease.

Authors:  Linnea Samsø Udholm; Simon Ladefoged Rasmussen; Thyge K Madsbøll; Mohammed Omairi; Alaa El-Hussuna
Journal:  Int J Colorectal Dis       Date:  2020-10-13       Impact factor: 2.796

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.